Silvestrini R, Daidone M G, Bolis G, Fontanelli R, Landoni F, Andreola S, Colombi R
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Gynecol Oncol. 1989 Oct;35(1):15-9. doi: 10.1016/0090-8258(89)90003-6.
The proliferative activities (3H-thymidine labeling index, LI) of 72 primary ovarian cancers and 76 metastatic lesions from untreated patients were evaluated. Overall, median LI values for primary and metastatic lesions were similar (7.8 vs 7.0%), but cell kinetics significantly differed in metastases from different sites. The LI of the primary tumor was unrelated to pathologic stage and histology, but was significantly correlated with histologic grading (P = .014). The prognostic relevance of LI was assessed for 43 untreated patients at stage III-IV (90% with bulky residual disease), treated after staging laparatomy with five cycles of cisplatin or of carboplatin. For 19 patients the LI was determined for both primary tumor and metastases, for 15 for the primary, and for 12 for the metastatic lesions. Complete remission (CR) was unrelated to pretreatment LI, although a trend toward a higher rate of CR was observed with rapidly proliferating tumors. Patients with slowly proliferating primary tumors had a higher probability of 1.5-year survival than patients with rapidly proliferating tumors (83 vs 50%). The difference was even greater between patients with both primary and metastatic lesions proliferating slowly (100%) and patients with at least one (61%) or both lesions proliferating rapidly (60%). Pretreatment LI was not predictive for survival in subgroups of patients who attained CR, but it was quite predictive for survival in patients responding only partially or not at all (90 vs 32%, P = .025).
对72例原发性卵巢癌以及76例未经治疗患者的转移病灶的增殖活性（3H-胸腺嘧啶核苷标记指数，LI）进行了评估。总体而言，原发性和转移病灶的LI中位数相似（7.8%对7.0%），但不同部位转移灶的细胞动力学存在显著差异。原发性肿瘤的LI与病理分期和组织学无关，但与组织学分级显著相关（P = 0.014）。对43例III-IV期未经治疗的患者（90%有大块残留病灶）在分期剖腹手术后接受五个周期顺铂或卡铂治疗，评估了LI的预后相关性。19例患者测定了原发性肿瘤和转移灶的LI，15例测定了原发性肿瘤的LI，12例测定了转移病灶的LI。完全缓解（CR）与预处理LI无关，尽管在增殖迅速的肿瘤中观察到CR率有升高趋势。原发性肿瘤增殖缓慢的患者1.5年生存率高于增殖迅速的患者（83%对50%）。原发性和转移病灶均增殖缓慢的患者（100%）与至少有一个病灶（61%）或两个病灶均增殖迅速的患者（60%）之间的差异更大。预处理LI对达到CR的患者亚组的生存无预测价值，但对仅部分缓解或未缓解的患者的生存有较好的预测价值（90%对32%，P = 0.025）。
